About Us
Juno Pharmaceuticals is a rapidly-growing global specialty pharmaceutical company that was founded in 2011 by group of experienced international pharmaceutical executives.
To date we have launched a wide range of differentiated generic and branded pharmaceutical products in our territories, with approvals pending for an extended list of additional products.
Our product portfolio and pipeline covers a broad spectrum of therapeutic areas and formats, including oral solid dosages, injectable medications, suspensions, ophthalmic solutions, creams and patches.
History
Juno at a Glance
Where Are We Based?
What Do We Offer?
What Are We Looking For?
If you would like to discuss a business opportunity with Juno, please contact Jesse Buckstein, Director of Corporate Development today.
Our Businesses
Please roll over the logos or map points for further information
A fully-integrated British pharmaceutical company offering complete product management solutions to its partners. Aspire specializes in the licensing, registration and commercialization of both branded and generic medicines, with a clear focus on value and sustainability.
Aspire has a proven track record of delivering service to its customers and value to its partners. It invests in product developments that are differentiated and designed to better meet the needs of UK healthcare professionals and patients alike.
Go to Website
Juno’s Australian subsidiary focuses on registering and promoting innovative product presentations and securing treatments for high-priority unmet medical needs. Juno aims to be a leading partner to hospitals across Australia in the provision of specialty hospital medicines and medication delivery systems.
The Juno Australia team has substantial expertise in ensuring reliable commercial activity for maturing brands and/or close-to-patent-expiry brands, which benefits our partners by allowing them to refocus important resources to new product launch opportunities. We are constantly seeking innovative products to in-licence or acquire for the Australian market, and we excel in the development of novel registration pathways for complex generic products.
Go to Website
SEP is a UK-based pan-European specialty pharmaceutical company that primarily focuses on products catering to the European urology and urogynaecology markets.
SEP seeks to acquire, license and distribute pharmaceutical products and medical devices aimed at its target markets. Its products are sold throughout Europe by SEP’s dedicated sales force and where SEP retains IP rights to products outside of Europe, it establishes distribution relationships with expert industry partners for ex-EU territories.
Go to Website
MDA is a Canadian pharmaceutical company principally engaged in commercializing top quality, hospital based, generic and value-added products. MDA is developing a sustainable & differentiated pharmaceutical business that delivers value to customers, business partners, & the Canadian healthcare system alike.
MDA’s strategic focus is on the in-licensing and commercialisation of specialty generics and hospital injectable medications, particularly those that face limited competition & inherent barriers to market entry. MDA also works with a select group of partners to develop limited and/or difficult to manufacture generics and novel drug delivery mechanisms that satisfy untapped market demand.
Go to Website
Kahma is a diversified South African healthcare company that distributes a comprehensive line of vaccines, niche retail & hospital generic medications, hospital-based medical devices, surgical equipment, and much more.
Kahma’s principal shareholders and senior managers were instrumental in building the first black economically empowered (BEE) healthcare company in South Africa (Litha Healthcare), which was listed on the South African Stock Exchange (JSE) before eventually being acquired by Endo in 2015. Their domestic regulatory expertise coupled with their premier network of hospital & retail contacts make Kahma a rising leader in the South African healthcare space.
Go to Website
Juno OTC focuses on sourcing, registering and distributing private label and branded over-the-counter (OTC) medications in Canada. Juno OTC’s management team has longstanding and extensive relationships with all of the leading Canadian pharmaceutical retailers and considerable expertise in ensuring best in class commercial supply chain and customer management.
We work with both our suppliers and customers alike to identify optimal new product opportunities within our market and we specialize in managing all aspects of our products’ commercialization processes, from licensing and registration through to ordering and distribution.
Our Capabilities
Global acquisition and in-licensing of specialty generic and branded pharmaceuticals and biologics, including mature brands and first-to-market generics. We utilize our access to medical specialists to identify key therapeutic needs/opportunities across our territories and leverage a global network of industry contacts to source ideal product development and supply partners.
Veteran regulatory affairs professionals with decades of industry experience. We have excellent relationships with the likes of the European Medicines Agency (EMA), the American Food and Drug Administration (FDA), Canada’s Therapeutic Products Directorate (TPD), Australia’s Therapeutic Goods Administration (TGA), and South Africa’s Medicines Control Council (MCC) and our team specializes in developing creative product submission strategies that reliably facilitate rapid market access for in-licensed products.
Numerous employees throughout our territories dedicated to reliably coordinating the movement of our products from point of origin to consumption.
Expert management of hospital tenders and retail relationships coupled with the development and successfully execution of novel product commercialization and reimbursement strategies.
In house IP experts who specialize in the evaluation of brand patent landscapes and the development of novel non-infringement and/or patent invalidation strategies.
“Juno will become a prominent international pharmaceutical company that supplies value-added and differentiated specialty products to global markets. Juno will build bridges to unmet medical needs through disciplined investment and successful application of creative business principles, ensuring that its customers and patient groups have access to the medicines they need at all times.”
Our Team
.
Ian Jacobson
Chief Executive Officer
Ian Jacobson has over 30 years of pharmaceutical industry experience.
Prior to founding Juno Pharmaceuticals, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010 and he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and he played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD.
Prior to his work at Arrow, Ian was involved with Par Pharmaceuticals (US) in the Office of the President, Genpharm Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive.
Ian Jacobson
Chief Executive Officer
Mark Roberts
Chief Executive Officer
Mark Roberts has worked in global pharmaceutical markets for over 20 years.
Before joining Juno, Mark worked at Zydus Cadila as VP Global Licensing (2009 – 2011) where he was responsible for establishing a global licensing business unit focused on generics, bio-generics and branded products.
Prior to his work at Zydus, Mark oversaw the set up and management of a new global licensing business unit at Pliva (division of Barr Labs, eventually acquired by Teva), where he had full responsibility for the establishment and expansion of Pliva’s licensing activities and strategic alliances in Europe, South Africa, Asia Pacific and North America. He also formerly worked for the Helm group from 1997-2003, where he ran pharmaceutical licensing and distribution for South Africa and the USA.
Mark Roberts
Chief Operating Officer
Craig Podolsky
Chief Financial Officer
Craig Podolsky has over 10 years of pharmaceutical industry experience.
Prior to co-founding Juno in 2011, Craig worked for Cobalt Pharmaceuticals in its business development group. He was responsible for negotiating product license and supply agreements for Cobalt’s OTC and generic divisions, and was Cobalt’s primary lead on all global M&A transactions.
Craig Podolsky
Chief Financial Officer
.
.
Jon May
Business Development Director
Jon May has over 20 years of global pharmaceutical product development experience.
Prior to joining Juno in 2016, Jon served as VP Strategic Development and was a key senior management team member at Pharmathen (2008-2016), where he principally oversaw and managed the company’s product portfolio, API functions, direct spend and strategic alliances.
Prior to his work at Pharmathen, Jon worked for Mylan (Merck Generics) from 1995-2008 in various technical functions, and prior to that he worked for SmithKline Beecham Animal Health in various product development and regulatory functions.
Jon May
Business Development Director
Andrew Brown
Head of Intellectual Property
Andrew Brown is a Chartered UK and European Patent Attorney with over 20 years’ of pharmaceutical industry experience. Before joining Juno in 2016, Andrew served as the Head of IP at Pharmathen, and prior to that he served in a myriad of high profile IP roles at various leading pharmaceutical companies, including Senior Patent Attorney at AstraZeneca and IP Director at Teva.
Andrew Brown
Head of Intellectual Property
Jesse Buckstein
Director of Corporate Development
Jesse joined Juno in 2014, where his responsibilities include spearheading due diligence and deal structuring on global M&A opportunities, negotiating and setting up joint ventures, designing and implementing tools to streamline Juno’s internal processes, and drafting and reviewing license and supply contracts with Juno’s contract manufacturing/product development partners.
Prior to joining Juno, Jesse worked in the commercial finance department of TD Bank, where he managed & actively added to a portfolio of over 100 diverse businesses, underwriting a wide range of acquisition, real estate, equipment, and working capital related loans on behalf of his clients. He previously worked for Tandem Expansion Fund, a growth capital investor in Canadian tech companies, where he assisted in acquisition-related due diligence and built a number of databases to help streamline the fund’s operations.
Jesse Buckstein
Director of Corporate Development
.
.
Richard Jacques Ph.D.
Licensing & Business Development Manager
Richard Jacques has over 10 years of pharmaceutical experience gained across a range of academic, industrial and business environments.
Prior to joining Juno in 2015, Richard obtained a Ph.D in small molecule-focused molecular pharmacology from the University of East Anglia’s School of Pharmacy, before subsequently moving into a postdoctoral teaching position at this institution. During this time, Richard forged academic research collaborations with numerous international pharmaceutical companies. Richard also formerly worked in industrial R&D for GlaxoSmithKline at GSK’s Medicines Research Centre.
Richard Jacques Ph.D.
Business Development Manager
CVS Murthy
General Manager India
CVS Murthy has over 20 years of pharmaceutical industry experience. He is responsible for managing Juno’s product sourcing and distribution from Indian suppliers and generally supporting Juno’s business development activities with its global partners.
Prior to joining Juno, Murthy served as General Manager – Indian Operations for Arrow Pharmaceuticals and prior to that he served in a range of business development roles for several leading Indian pharmaceutical companies, including Dr. Reddy’s and Alembic.
CVS Murthy
General Manager India
Nandkishor Karekar
Supply Chain Manager
Nandkishor Karekar has over 20 years of commercial and supply chain experience, including over 12 years in the pharmaceutical industry. He is primarily responsible for overseeing supply chain activities for the Juno group’s companies and supporting Juno’s international business development activities.
Prior to joining Juno, Nandkishor worked for GXP Pharma as their Manager, Supply Chain and he previously worked in various commercial and supply chain roles for the likes of Lupin Pharmaceuticals, Boehringer Mannheim, and Ipca Laboratories.
Nandkishor Karekar
Supply Chain Manager
.
.
News
Juno Pharmaceuticals announced today that it has acquired Amneal Pharmaceuticals' injectables, ophthalmic, and oncology product portfolios in Australia.
“Juno is excited to add the Amneal Australia hospital injectable, ophthalmic, and oncology range to its growing portfolio. This Amneal portfolio complements many of Juno's existing assets nicely and Juno is particularly excited to be managing products such as Bicnu (carmustine),” said CEO and Managing Director of Juno Australia, Mark Crotty.
Juno is a rapidly-growing local Australian business that recorded its first full year of commercial sales in 2016. Juno’s business model is based on partnering across all stages of the commercial cycle and has a core focus on local Australian hospital customer needs. The acquisition of Amneal's portfolio is Juno Australia’s first since its formation in 2013 and when added to its existing product portfolio and strong pipeline, the acquisition is expected to position Juno as one of the largest generic injectable product hospital suppliers in the Australian market.
The acquisition takes effect from August 31st, 2017. Juno will work with Amneal to ensure a smooth transition of the business with suppliers and customers.
For all queries please contact:
Mark Crotty, +61 424 152 881
The management team of Juno Pharmaceuticals Inc. (Juno) is pleased to announce the launch of Juno OTC Inc. (Juno OTC).
Headquartered in Canada, Juno is an international specialty pharmaceutical and medical devices group that focuses on meeting the various product needs of physicians, pharmacy chains, and patients alike across its active markets. Juno was founded in 2011 and has grown rapidly over the past six years, currently holding offices in the UK, EU, Australia, and South Africa.
The launch of Juno OTC provides the group with an excellent opportunity to fill some of the most pressing OTC product and service needs currently present in the Canadian retail pharmacy market. Juno’s principals are confident that their extensive knowledge of the Canadian marketplace, their experience in the OTC business and their many longstanding relationships with both domestic retail partners and global product suppliers will serve the group extremely well in its latest endeavor.
Commenting on the launch of Juno OTC, Ian Jacobson, Chief Executive Officer of Juno said:
“Juno is at an exciting juncture in its development. Having already established strong commercial footprints in the hospital and retail prescription spaces, the launch of Juno OTC provides us with an excellent opportunity to diversify our business into a new vertical. Our management team has decades of experience working alongside and supporting all of the leading retail pharmacy chains in Canada and we are confident that our extensive relationships with these industry partners will prove to be an excellent platform for rapid growth.”
For further information please contact:
Jesse Buckstein, Director of Corporate Development
Tel: +1 905 881 4410 x203
Email: jesse.buckstein@junopharm.com
About Juno
Juno Pharmaceuticals Inc. is an international specialty pharmaceutical company with operations in Canada, the UK, EU, Australia, and South Africa. Juno works closely with its portfolio companies and global network of product suppliers to identify and in-license value-added and differentiated specialty generics, brands and medical devices to ensure that customers and patient groups alike across Juno’s territories have access to the medicines they require.
The management team of Speciality European Pharma Limited (SEP), today announced their acquisition of SEP from its venture capital shareholders, with the backing of Juno Pharmaceuticals Inc. (Juno), an international specialty pharmaceutical company and leading life science investor.
Headquartered in the UK, SEP is a specialty pharmaceutical and medical devices group that focuses on meeting the needs of the specialist physician. SEP was founded in 2006 and has grown rapidly over the past five years, with a commercial presence in much of Europe and a desire to grow beyond. The MBO provides SEP with the opportunity to not only continue its growth strategy with existing products but to also invest for the long-term in the untapped potential in its proprietary development portfolio. Near-term objectives for this investment include United States approval of Bulkamid, the group’s urethral bulking agent, and EU approval of Arthrosamid, the group’s synovial implant for osteoarthritis.
Commenting on the MBO, Patrick Banks, Chief Executive Officer of SEP, said:
“SEP is at an exciting juncture in its development. Having already established a strong commercial footprint in the EU, SEP acquired Contura, a medical devices business, in April 2013. This acquisition has proved a great success and with the increased financial strength that has come from substantial revenue growth and the backing that now comes from Juno, SEP is well placed to make the significant investments required to deliver its true potential.”
Commenting on the MBO, Ian Jacobson, Chief Executive Officer of Juno, said:
“We are very excited about our acquisition of SEP and partnership with its management team. SEP’s niche product portfolio and strategic focus aligns perfectly with Juno’s corporate mission and we look forward to building on SEP’s impressive track record of growth. We view SEP as a company that has only begun to realize its considerable potential and we are confident that in partnership with its existing management team, we can build SEP into one of Europe’s leading pharmaceutical and medical device companies.”
-ENDS-
For further information please contact:
SEP Tel: +44 (0)20 7421 7400
Patrick Banks, Chief Executive Officer
MELBOURNE, AUSTRALIA–Celgene Pty and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia.
Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia.
“By combining forces with Juno Pharmaceuticals, we are complementing our innovative product with a strong national key account management team that has relationships across the hospital market,” said George Varkanis, Celgene Vice President and Managing Director (Australia and New Zealand).
The partnership continues the trend for Juno Pharmaceuticals in partnering with leading global pharmaceutical companies. It follows a recent announcement that Juno Pharmaceuticals made with Photocure ASA to bring the unique product Hexvix® to the Australian and New Zealand markets.
“We look forward to delivering a strong partnership model with Celgene on Vidaza® and exploring any opportunities that exist throughout the products lifecycle,” said Juno Pharmaceuticals CEO George Katsanos.
Financial details of the joint venture were not disclosed.
For more information please visit www.junopharm.com.au.
A newly formed consortium consisting of Westrate Trade and Invest Proprietary Limited (Westrate) and Immunotek Proprietary Limited (Immunotek) will acquire the South African vaccine and medical device businesses from Litha Healthcare Group Proprietary Limited (Litha), an Endo International plc (Endo) company. The transaction is expected to be concluded in the fourth quarter of 2015, subject to regulatory consents.
The consortium, which comprises of two synergistic entities, is a majority black-owned and wholly South African partnership led by the Litha Group’s former CEO (Selwyn Kahanovitz), former Deputy CEO (Morena Makhoana), and former CFO (Martin Kahanovitz).
The acquisition comes soon after the de-listing of Litha Healthcare Group by Endo in February 2015 and will include Litha’s interests in The Biovac Institute, a public-private partnership with the South African government.
“We are excited about the opportunity to continue to build these businesses. We know and understand them very well and we are extremely pleased to conclude a transaction of this nature,” says Morena Makhoana.
The consortium will continue to operate the acquired businesses from their respective locations and all staff will be retained within these businesses.
ENDS
About the Consortium
Immunotek is a South African company with a primary focus on the provision of vaccines to both the private and public healthcare sectors.
Westrate is a diversified healthcare company that imports and distributes medical/dental devices and consumables to the South African public and private healthcare sectors.
For further information please contact:
Name: Gaby Lobban Tel: +27 (0) 82 900 9270
Email: gaby@zumbudda.guru
Aspire Pharma is pleased to announce the launch of its new product, Biquelle XL tablets, which is the latest addition to Aspire Pharma's cost-saving range of prolonged release medicines. Biquelle XL is a prolonged-release tablet of quetiapine indicated for the treatment of schizophrenia and bipolar disorder, and as an add-on treatment for major depressive episodes in patients with Major Depressive Disorder.
To find out more about Biquelle XL, please email info@aspirepharma.co.uk or ring +44 (0) 1730 231148+44 (0) 1730 231148.
Contact
Head Office:
Juno Pharmaceuticals Inc.
555 Richmond Street West, Suite 1004, Toronto,
Ontario M5V 3B1, Canada
+1 905 881 4410 Ext 203
Business Development:
Juno Pharmaceuticals Inc.
1st Floor, The Coach House, Cross Heyes,
Malmesbury SN16 9BE
+44 (0) 1666 848 450